Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback